GlassScriptPhysician profile
Woojin Joo
NPI 1780110338
$4,940.66
in general payments reported to CMS, 2019-2025
22 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $975 · 2022: $1,750 · 2023: $1,087 · 2024: $636 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,031.94 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $895.88 | 2021-2025 | |
| Lilly USA, LLC | $666.78 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $565.75 | 2021-2025 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.99 | 2021-2025 | Jardiance |
| Pfizer INC. | $326.92 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.22 | 2022-2025 | |
| Dexcom, INC. | $165.97 | 2021-2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $119.26 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $66.06 | 2022 | |
| Sumitomo Pharma America, INC. | $55.64 | 2025 | Gemtesa |
| Abbott Laboratories | $45.34 | 2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $42.82 | 2023 | Verquvo, Belsomra |
| Amarin Pharma, INC. | $40.91 | 2021 | |
| Seqirus USA INC | $38.11 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37.84 | 2022-2024 | Farxiga |
| Gilead Sciences, INC. | $31.98 | 2023 | |
| Mannkind Corporation | $30.02 | 2025 | |
| Aimmune Therapeutics, INC. | $25.31 | 2024 | |
| Medline Industries LP | $24.92 | 2025 | |
| Glaxosmithkline, LLC. | $21.92 | 2023 | Arexvy, Shingrix |
| Exact Sciences Corporation | $17.08 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Woojin Joo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.